Genentech to Present New Data Advancing Its Obesity Portfolio at the American Diabetes Association’s 2026 Scientific Sessions
Late-breaking Phase II data highlight enicepatide’s (CT-388) efficacy and safety, reinforcing its potential to deliver best-in-class weight loss across a broad population of people living with overweight or obesity
Late-breaking data from the Phase II ZUPREME-1 trial showcase petrelintide’s efficacy, safety, and compelling tolerability profile, which has the potential to redefine the weight management experience for people living with overweight or obesity
A Phase II multi-arm trial evaluating enicepatide and petrelintide fixed-dose combinations will be initiated towards mid-2026 to develop a differentiated treatment option
Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that new data from its obesity portfolio will be presented at the 2026 Scientific Sessions of the American Diabetes Association® (ADA). The insights demonstrate significant progress in addressing a range of unmet needs for people living with obesity or overweight such as long-term treatment adherence, which could be supported by a favorable safety and tolerability profile.
